Apogenix GmbH Company Contacts

Apogenix develops innovative immunotherapeutics for the treatment of cancer and viral infections, such as COVID-19. The company has built a promising pipeline of drug candidates that target different TNFSF-dependent signaling pathways, thereby reducing lymphopenia and inflammatory cell death in patients... Read More

Contacts

Country

Germany

City

Headquarters

undefined, DE

Profile

Founded

2005

Industry

Biotechnology Research

Size

51 - 200

Specialties

Development of immunotherapeutics, TNF superfamily signaling, Drug candidates for cancer treatment, CD95, Glioblastoma, Myelodysplastic syndromes, COVID-19

Funding

Total Rounds

Last Round

Mon Feb 15 2016

Last Round Series

Grant

Last Round Raised

$ 3,342,820

Apogenix GmbH Company Contacts

Apogenix GmbH Add to my CRM

Apogenix GmbH